Skip to main content
SpringerLink
Log in

Faecal Microbiota Transplantation as Emerging Treatment in European Countries

  • Chapter
  • First Online:
Updates on Clostridium difficile in Europe

Part of the book series: Advances in Experimental Medicine and Biology ((AMIDPH,volume 1050))

Abstract

Clostridium difficile infection (CDI) is one of the most common healthcare-associated infections in the world and is a leading cause of morbidity and mortality in hospitalized patients.

Although several antibiotics effectively treat CDI, some individuals do not respond to these drugs and may be cured by transplanting stool from healthy donors. This procedure, termed Faecal Microbiota Transplantation (FMT), has demonstrated remarkable efficacy as a treatment for recurrent CDI.

FMT has also been investigated in other diseases and disorders where perturbations to the gut microbiota have been theorized to play a causative role in pathogenesis and severity, such as inflammatory bowel disease (IBD). Although FMT is currently not recommended to cure IBD patients in clinical practice, several studies have recently been carried out with promising results. The aim of future research is therefore to standardize protocols and develop FMT as a therapeutic option for these patients.

This review summarizes data on the use of FMT as a treatment for CDI and IBD, with special attention given to studies conducted in European countries.

All authors contributed to writing the paper and had full control over preparation of manuscript; all authors approved the final draft manuscript.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 139.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 179.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Anderson JL, Edney RJ, Whelan K (2012) Systematic review: faecal microbiota transplantation in the management of inflammatory bowel disease. Aliment Pharmacol Ther 36:503–516

    Article  CAS  Google Scholar 

  • Angelberger S, Reinisch W, Makristathis A et al (2013) Temporal bacterial community dynamics vary among ulcerative colitis patients after fecal microbiota transplantation. Am J Gastroenterol 108:1620–1630

    Article  CAS  Google Scholar 

  • Asha NJ, Tompkins D, Wilcox MH (2006) Comparative analysis of prevalence, risk factors, and molecular epidemiology of antibiotic-associated diarrhea due to Clostridium difficile, Clostridium perfringens, and Staphylococcus aureus. J Clin Microbiol 44:2785–2791

    Article  CAS  Google Scholar 

  • Bafeta A, Yavchitz A, Riveros C et al (2017) Methods and reporting studies assessing fecal microbiota transplantation: a systematic review. Ann Intern Med 167:34–39

    Article  Google Scholar 

  • Bagdasarian N, Rao K, Malani PN (2015) Diagnosis and treatment of Clostridium difficile in adults: a systematic review. JAMA 313:398–408

    Google Scholar 

  • Bak S, Choi H, Lee J (2017) Fecal microbiota transplantation for refractory Crohn’s disease. Intest Res 15:244–248

    Article  Google Scholar 

  • Barbut F, Mastrantonio P, Delmée M et al (2007) Prospective study of Clostridium difficile infections in Europe with phenotypic and genotypic characterisation of the isolates. Clin Microbiol Infect 13:1048–1057

    Google Scholar 

  • Bassler D, Briel M, Montori VM et al (2010) Stopping randomized trials early for benefit and estimation of treatment effects: systematic review and meta-regression analysis. JAMA 303:1180–1187

    Article  CAS  Google Scholar 

  • Bauer MP, Notermans DW, van Benthem BH et al (2011) Clostridium difficile infection in Europe: a hospital-based survey. Lancet 377:63–73

    Google Scholar 

  • Bennet JD, Brinkman M (1989) Treatment of ulcerative colitis by implantation of normal colonic flora. Lancet 1:164

    Article  CAS  Google Scholar 

  • Borody TJ, George L, Andrews P et al (1989) Bowel-flora alteration: a potential cure for inflammatory bowel disease and irritable bowel syndrome? Med J Aust 150:604

    CAS  PubMed  Google Scholar 

  • Borody TJ, Leis S, McGrath K (2001) Treatment of chronic constipation and colitis using human probiotic infusions, Probiotics, prebiotics and new foods conference. Universita Urbaniana, Rome

    Google Scholar 

  • Borody TJ, Warren EF, Leis S et al (2003) Treatment of ulcerative colitis using fecal bacteriotherapy. J Clin Gastroenterol 37:42–47

    Article  Google Scholar 

  • Borody TJ, Campbell J, Torres M et al (2011a) Reversal of idiopathic thrombocytopenic purpura [ITP] with fecal microbiota transplantation [FMT]. Am J Gastroenterol 106:S352

    Google Scholar 

  • Borody TJ, Torres M, Campbell J et al (2011b) Reversal of inflammatory bowel disease (IBD) with recurrent faecal microbiota transplants (FMT). Am J Gastroenterol 106:S366–S366

    Google Scholar 

  • Borren NZ, Ghadermarzi S, Hutfless S et al (2017) The emergence of Clostridium difficile infection in Asia: a systematic review and meta-analysis of incidence and impact. PLoS One 12:e0176797

    Google Scholar 

  • Brandt LJ, Aroniadis OC, Mellow M et al (2012) Long-term follow-up of colonoscopic fecal microbiota transplant for recurrent Clostridium difficile infection. Am J Gastroenterol 107:1079–1087

    Google Scholar 

  • Cammarota G, Ianiro G, Cianci R et al (2015a) The involvement of gut microbiota in inflammatory bowel disease pathogenesis: potential for therapy. Pharmacol Ther 149:191–212

    Article  CAS  Google Scholar 

  • Cammarota G, Ianiro G, Magalini S et al (2015b) Decrease in surgery for Clostridium difficile infection after starting a program to transplant fecal microbiota. Ann Intern Med 163:487–488

    Google Scholar 

  • Cammarota G, Masucci L, Ianiro G et al (2015c) Randomised clinical trial: faecal microbiota transplantation by colonoscopy vs. vancomycin for the treatment of recurrent Clostridium difficile infection. Aliment Pharmacol Ther 41:835–843

    Google Scholar 

  • Cammarota G, Ianiro G, Tilg H et al (2017) European consensus conference on faecal microbiota transplantation in clinical practice. Gut 66:569–580

    Article  Google Scholar 

  • Chu ND, Smith MB, Perrotta AR et al (2017) Profiling living bacteria informs preparation of fecal microbiota transplantations. PLoS One 12:e0170922

    Article  Google Scholar 

  • Cohen SH, Gerding DN, Johnson S, Society for Healthcare Epidemiology of America, Infectious Diseases Society of America et al (2010) Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol 31:431–455

    Article  Google Scholar 

  • Colman RJ, Rubin DT (2014) Fecal microbiota transplantation as therapy for inflammatory bowel disease: a systematic review and meta-analysis. J Crohns Colitis 8:1569–1581

    Article  Google Scholar 

  • Costello SP, Conlon MA, Vuaran MS et al (2015) Faecal microbiota transplant for recurrent Clostridium difficile infection using long-term frozen stool is effective: clinical efficacy and bacterial viability data. Aliment Pharmacol Ther 42:1011–1018

    Google Scholar 

  • Costello SP, Soo W, Bryant RV et al (2017a) Systematic review with meta-analysis: faecal microbiota transplantation for the induction of remission for active ulcerative colitis. Aliment Pharmacol Ther 46:213–224

    Article  CAS  Google Scholar 

  • Costello S, Waters O, Bryant R et al (2017b) Short duration, low intensity pooled faecal microbiota transplantation induces remission in patients with mild-moderately active ulcerative colitis: a randomised controlled trial. J Crohns Colitis 11(suppl 1):S23

    Article  Google Scholar 

  • Cui B, Feng Q, Wang H et al (2015a) Fecal microbiota transplantation through mid-gut for refractory Crohn’s disease: safety, feasibility, and efficacy trial results. J Gastroenterol Hepatol 30:51–58

    Article  CAS  Google Scholar 

  • Cui B, Li P, Xu L et al (2015b) Step-up fecal microbiota transplantation strategy: a pilot study for steroid-dependent ulcerative colitis. J Transl Med 13:298

    Article  Google Scholar 

  • Debast SB, Bauer MP, Kuijper EJ et al (2014) European society of clinical microbiology and infectious diseases: update of the treatment guidance document for Clostridium difficile infection. Clin Microbiol Infect 20(Suppl 2):1–26

    Google Scholar 

  • Dutta SK, Girotra M, Garg S et al (2014) Efficacy of combined jejunal and colonic fecal microbiota transplantation for recurrent Clostridium difficile infection. Clin Gastroenterol Hepatol 12:1572–1576

    Google Scholar 

  • European Surveillance of Clostridium difficile infections. Surveillance protocol version 2.2. European Centre for Disease Prevention and Control. Stockholm: ECDC (2015) https://doi.org/10.2900/44795. https://ecdc.europa.eu/sites/portal/files/media/en/publications/Publications/Europeansurveillance-clostridium-difficile.v2FINAL.pdf. Latest Access July 2017

  • Fang S, Kraft CS, Dhere T et al (2016) Successful treatment of chronic pouchitis utilizing fecal microbiota transplantation [FMT]: a case report. Int J Color Dis 31:1093–1094

    Article  Google Scholar 

  • Garborg K, Waagsbø B, Stallemo A et al (2010) Results of faecal donor instillation therapy for recurrent Clostridium difficile-associated diarrhoea. Scand J Infect Dis 42:857–861

    Google Scholar 

  • Gordon H, Harbord M (2014) A patient with severe Crohn’s colitis responds to faecal microbiota transplantation. J Crohns Colitis 8:256–257

    Article  Google Scholar 

  • Goyal A, Chu A, Calabro K et al (2016) Safety and efficacy of fecal microbiota transplant in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 63:S212

    Google Scholar 

  • Grewal CS, Sood A, Mehta V et al (2016) Role of fecal microbiota transplantation in patients with steroid dependent ulcerative colitis. Am J Gastroenterol 111:S1252–S1253

    Article  Google Scholar 

  • Hagel S, Fischer A, Ehlermann P et al (2016) Fecal microbiota transplant in patients with recurrent Clostridium difficile infection. Dtsch Arztebl Int 113(35–36):583–589

    Google Scholar 

  • Hamilton MJ, Weingarden AR, Sadowsky MJ et al (2012) Standardized frozen preparation for transplantation of fecal microbiota for recurrent Clostridium difficile infection. Am J Gastroenterol 107:761–767

    Google Scholar 

  • Hirsch BE, Saraiya N, Poeth K et al (2015) Effectiveness of fecal-derived microbiota transfer using orally administered capsules for recurrent Clostridium difficile infection. BMC Infect Dis 15:191

    Google Scholar 

  • Hota SS, Sales V, Tomlinson G et al (2017) Oral vancomycin followed by fecal transplantation versus tapering oral vancomycin treatment for recurrent Clostridium difficile infection: an open-label, randomized controlled trial. Clin Infect Dis 64:265–271

    Google Scholar 

  • Ianiro G, Bibbò S, Scaldaferri F et al (2014) Fecal microbiota transplantation in inflammatory bowel disease: beyond the excitement. Medicine (Baltimore) 93(19):e97

    Article  Google Scholar 

  • Ianiro G, Valerio L, Masucci L et al (2017) Predictors of failure after single faecal microbiota transplantation in patients with recurrent Clostridium difficile infection: results from a 3-year, single-centre cohort study. Clin Microbiol Infect 23:337.e1–337.e3

    Google Scholar 

  • Ishikawa D, Sasaki T, Osada T et al (2017) Changes in intestinal microbiota following combination therapy with fecal microbial transplantation and antibiotics for ulcerative colitis. Inflamm Bowel Dis 23:116–125

    Article  Google Scholar 

  • Jacob V, Crawford C, Cohen-Mekelburg S et al (2016) Fecal microbiota transplantation via colonoscopy is safe and effective in active ulcerative colitis. In: Advances in inflammatory bowel diseases. December 8–10, 2016. Orlando

    Google Scholar 

  • Jorup-Ronstrom C, Hakanson A, Sandell S et al (2012) Fecal transplant against relapsing Clostridium difficile-associated diarrhea in 32 patients. Scand J Gastroenterol 47:548–552

    Google Scholar 

  • Kahn SA, Goeppinger SR, Vaughn BP et al (2014) Tolerability of colonoscopic fecal microbiota transplantation in IBD. Gastroenterology 146:S-581

    Article  Google Scholar 

  • Kao D, Hotte N, Gillevet P et al (2014) Fecal microbiota transplantation inducing remission in Crohn’s colitis and the associated changes in fecal microbial profile. J Clin Gastroenterol 48:625–628

    Article  Google Scholar 

  • Karakan T, Ibis M, Cindoruk Z et al (2016) Faecal microbiota transplantation as a rescue therapy for steroid-dependent and/or non-responsive patients with ulcerative colitis: a pilot study. In: 11th congress of the European Crohn’s and colitis organisation. March 16–19, 2016. Amsterdam

    Google Scholar 

  • Kassam Z, Hundal R, Marshall JK et al (2012) Fecal transplant via retention enema for refractory or recurrent Clostridium difficile infection. Arch Intern Med 172:191–193

    Google Scholar 

  • Kelly CR, Ihunnah C, Fischer M et al (2014) Fecal microbiota transplant for treatment of Clostridium difficile infection in immunocompromised patients. Am J Gastroenterol 109:1065–1071

    Google Scholar 

  • Khan MA, Sofi AA, Ahmad U et al (2014) Efficacy and safety of, and patient satisfaction with, colonoscopic-administered fecal microbiota transplantation in relapsing and refractory community- and hospital-acquired Clostridium difficile infection. Can J Gastroenterol Hepatol 28:434–438

    Google Scholar 

  • Kump PK, Grochenig HP, Lackner S et al (2013) Alteration of intestinal dysbiosis by fecal microbiota transplantation does not induce remission in patients with chronic active ulcerative colitis. Inflamm Bowel Dis 19:2155–2165

    Article  Google Scholar 

  • Kump PK, Wurm P, Gröchenig HP et al (2015) Impact of antibiotic treatment before faecal microbiota transplantation [FMT] in chronic active ulcerative colitis. United European Gastroenterol J 3(5Suppl):A437

    Google Scholar 

  • Kunde S, Pham A, Bonczyk S et al (2013) Safety, tolerability, and clinical response after fecal transplantation in children and young adults with ulcerative colitis. J Pediatr Gastroenterol Nutr 56:597–601

    Article  Google Scholar 

  • Landy J, Walker AW, Li JV et al (2015) Variable alterations of the microbiota, without metabolic or immunological change, following faecal microbiota transplantation in patients with chronic pouchitis. Sci Rep 5:12955

    Article  CAS  Google Scholar 

  • Lee CH, Belanger JE, Kassam Z et al (2014) The outcome and long-term follow-up of 94 patients with recurrent and refractory Clostridium difficile infection using single to multiple fecal microbiota transplantation via retention enema. Eur J Clin Microbiol Infect Dis 33:1425–1428

    Google Scholar 

  • Lee CH, Steiner T, Petrof EO et al (2016) Frozen vs fresh fecal microbiota transplantation and clinical resolution of diarrhea in patients with recurrent Clostridium difficile infection: a randomized clinical trial. JAMA 315:142–149

    Google Scholar 

  • Lessa FC, Mu Y, Bamberg WM et al (2015) Burden of Clostridium difficile infection in the United States. N Engl J Med 372:825–834

    Google Scholar 

  • Li YT, Cai HF, Wang ZH et al (2016) Systematic review with meta-analysis: long-term outcomes of faecal microbiota transplantation for Clostridium difficile infection. Aliment Pharmacol Ther 43:445–457

    Google Scholar 

  • Ma GK, Brensinger CM, Wu Q et al (2017) Increasing incidence of multiply recurrent Clostridium difficile infection in the United States: a cohort study. Ann Intern Med 167:152–158. https://doi.org/10.7326/M16-2733

  • MacConnachie AA, Fox R, Kennedy DR et al (2009) Faecal transplant for recurrent Clostridium difficile-associated diarrhoea: a UK case series. QJM 102:781–784

    Google Scholar 

  • Mandalia A, Ward A, Tauxe W et al (2016) Fecal transplant is as effective and safe in immunocompromised as non-immunocompromised patients for Clostridium difficile. Int J Color Dis 31:1059–1060

    Google Scholar 

  • Mattila E, Uusitalo-Seppala R, Wuorela M et al (2012) Fecal transplantation, through colonoscopy, is effective therapy for recurrent Clostridium difficile infection. Gastroenterology 142:490–496

    Google Scholar 

  • McDonald LC, Killgore GE, Thompson A et al (2005) An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 353:2433–2441

    Google Scholar 

  • Meighani A, Hart BR, Mittal C et al (2016) Predictors of fecal transplant failure. Eur J Gastroenterol Hepatol 28:826–830

    Google Scholar 

  • Millan B, Park H, Hotte N et al (2016) Fecal microbial transplants reduce antibiotic-resistant genes in patients with recurrent Clostridium difficile infection. Clin Infect Dis 62:1479–1486

    Google Scholar 

  • Moayyedi P, Surette MG, Kim PT et al (2015) Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial. Gastroenterology 149:102–109

    Article  Google Scholar 

  • Mullane KM, Cornely OA, Crook DW et al (2013) Renal impairment and clinical outcomes of Clostridium difficile infection in two randomized trials. Am J Nephrol 38:1–11

    Article  Google Scholar 

  • Nishida A, Imaeda H, Ohno M et al (2017) Efficacy and safety of single fecal microbiota transplantation for Japanese patients with mild to moderately active ulcerative colitis. J Gastroenterol 52:476–482

    Article  Google Scholar 

  • Paramsothy S, Kamm MA, Kaakoush NO et al (2017a) Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial. Lancet 389:1218–1228

    Article  Google Scholar 

  • Paramsothy S, Paramsothy R, Rubin DT et al (2017b) Faecal microbiota transplantation for inflammatory bowel disease: a systematic review and meta-analysis. J Crohns Colitis 11:1180–1199. https://doi.org/10.1093/ecco-jcc/jjx063

    Article  PubMed  Google Scholar 

  • Polak P, Freibergerova M, Jurankova J et al (2011) First experiences with faecal bacteriotherapy in the treatment of relapsing pseudomembranous colitis due to Clostridium difficile. Klin Mikrobiol Infekc Lek 17:214–217

    Google Scholar 

  • Rossen NG, Fuentes S, van der Spek et al (2015) Findings from a randomized controlled trial of fecal transplantation for patients with ulcerative colitis. Gastroenterology 149:110–118

    Article  Google Scholar 

  • Satokari R, Mattila E, Kainulainen V et al (2015) Simple faecal preparation and efficacy of frozen inoculum in faecal microbiota transplantation for recurrent Clostridium difficile infection—an observational cohort study. Aliment Pharmacol Ther 41:46–53

    Article  CAS  Google Scholar 

  • Scaldaferri F, Pecere S, Bruno G et al (2015) An open-label, pilot study to assess feasibility and safety of fecal microbiota transplantation in patients with mild-moderate ulcerative colitis: preliminary results. J Crohns Colitis 9:S278

    Google Scholar 

  • Schmid M, Frick JS, Malek N et al (2017) Successful treatment of pouchitis with Vedolizumab, but not fecal microbiota transfer (FMT), after proctocolectomy in ulcerative colitis. Int J Color Dis 32:597–598

    Article  Google Scholar 

  • Sokol H, Pigneur B, Watterlot L et al (2008) Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci U S A 105:16731–16736

    Google Scholar 

  • Staley C, Hamilton MJ, Vaughn BP et al (2017) Successful resolution of recurrent Clostridium difficile infection using freeze-dried, encapsulated fecal microbiota; pragmatic cohort study. Am J Gastroenterol 112:940–947

    Google Scholar 

  • Stallmach A, Lange K, Buening J et al (2016) Fecal microbiota transfer in patients with chronic antibioticrefractory pouchitis. Am J Gastroenterol 111:441–443

    Google Scholar 

  • Stevens V, Dumyati G, Fine LS et al (2011) Cumulative antibiotic exposures over time and the risk of Clostridium difficile infection. Clin Infect Dis 53:42–48

    Article  Google Scholar 

  • Surawicz CM, Brandt LJ, Binion DG et al (2013) Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol 108:478–498

    Google Scholar 

  • Suskind DL, Brittnacher MJ, Wahbeh G et al (2015) Fecal microbial transplant effect on clinical outcomes and fecal microbiome in active Crohn’s disease. Inflamm Bowel Dis 21:556–563

    Article  Google Scholar 

  • Swaminath A (2014) The power of poop: patients getting ahead of their doctors using self-administered fecal transplants. Am J Gastroenterol 109:777–778

    Article  Google Scholar 

  • Tang G, Yin W, Liu W (2017) Is frozen fecal microbiota transplantation as effective as fresh fecal microbiota transplantation in patients with recurrent or refractory Clostridium difficile infection: a meta-analysis? Diagn Microbiol Infect Dis 88:322–329

    Google Scholar 

  • Tauxe WM, Haydek JP, Rebolledo PA et al (2016) Fecal microbiota transplant for Clostridium difficile infection in older adults. Ther Adv Gastroenterol 9:273–281

    Google Scholar 

  • van Nood E, Vrieze A, Nieuwdorp M et al (2013) Duodenal infusion of donor faeces for recurrent Clostridium difficile. N Engl J Med 368:407–415

    Google Scholar 

  • Vaughn BP, Vatanen T, Allegretti JR et al (2016) Increased intestinal microbial diversity following fecal microbiota transplant for active Crohn’s disease. Inflamm Bowel Dis 22:2182–2190

    Article  Google Scholar 

  • Vermeire S, Joossens M, Verbeke K et al (2016) Donor species richness determines faecal microbiota transplantation success in inflammatory bowel disease. J Crohns Colitis 10:387–394

    Article  Google Scholar 

  • Warny M, Pepin J, Fang A et al (2005) Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 366:1079–1084

    Google Scholar 

  • Wei Y, Zhu W, Gong J et al (2015) Fecal microbiota transplantation improves the quality of life in patients with inflammatory bowel disease. Gastroenterol Res Pract 2015:517597

    Article  Google Scholar 

  • Wei Y, Gong J, Zhu W et al (2016) Pectin enhances the effect of fecal microbiota transplantation in ulcerative colitis by delaying the loss of diversity of gut flora. BMC Microbiol 16:1–9

    Article  Google Scholar 

  • Youngster I, Russell GH, Pindar C et al (2014a) Oral, capsulized, frozen fecal microbiota transplantation for relapsing Clostridium difficile infection. JAMA 312:1772–1778

    Article  CAS  Google Scholar 

  • Youngster I, Sauk J, Pindar C et al (2014b) Fecal microbiota transplant for relapsing Clostridium difficile infection using a frozen inoculum from unrelated donors: a randomized, open-label, controlled pilot study. Clin Infect Dis 58:1515–1522

    Google Scholar 

  • Youngster I, Mahabamunuge J, Systrom HK et al (2016) Oral, frozen fecal microbiota transplant (FMT) capsules for recurrent Clostridium difficile infection. BMC Med 14:134

    Google Scholar 

  • Zainah H, Hassan M, Shiekh-Sroujieh L et al (2014) Intestinal microbiota transplantation, a simple and effective treatment for severe and refractory Clostridium difficile infection. Dig Dis Sci 60:181–185

    Google Scholar 

  • Zhang T, Cui B, Li P et al (2016) Short-term surveillance of cytokines and C-reactive protein cannot predict efficacy of fecal microbiota transplantation for ulcerative colitis. PLoS One 11:e0158227

    Article  Google Scholar 

  • Zimlichman E, Henderson D, Tamir O et al (2013) Health care-associated infections. JAMA Intern Med 173:2039–2046

    Article  Google Scholar 

Download references

Conflict-of-Interest Statement

James McIlroy has received personal fees from EnteroBiotix during the conduct of this manuscript.

Author information

Authors and Affiliations

  1. Section of Gastroenterology, S.Elia – Raimondi Hospital, Caltanissetta, Italy

    Marcello Maida

  2. School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Aberdeen, UK

    James Mcilroy

  3. Gastroenterological Area, Fondazione Policlinico Universitario Gemelli, Università Cattolica del Sacro Cuore, Rome, Italy

    Gianluca Ianiro & Giovanni Cammarota

Authors
  1. Marcello Maida
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. James Mcilroy
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gianluca Ianiro
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Giovanni Cammarota
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Giovanni Cammarota .

Editor information

Editors and Affiliations

  1. Former Research Director in the Department of Infectious Diseases, National Institute of Health (ISS), Rome, Italy

    Paola Mastrantonio

  2. Department for Microbiological Research, National Laboratory of Health, Environment and Food (NLZOH), Maribor, Slovenia

    Maja Rupnik

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Maida, M., Mcilroy, J., Ianiro, G., Cammarota, G. (2018). Faecal Microbiota Transplantation as Emerging Treatment in European Countries. In: Mastrantonio, P., Rupnik, M. (eds) Updates on Clostridium difficile in Europe. Advances in Experimental Medicine and Biology(), vol 1050. Springer, Cham. https://doi.org/10.1007/978-3-319-72799-8_11

Download citation

Publish with us

Policies and ethics

Search

Navigation